Skip to main content
Download PDF
Download ePub

Synthesis and tyrosinase inhibitory activities of novel isopropylquinazolinones

BMC Chemistry volume 17, Article number: 65 (2023) Cite this article

Abstract

To find new anti-browning and whitening agents in this study, new series of isopropylquinazolinone derivatives were designed and synthesized. All derivatives were evaluated as possible tyrosinase inhibitors and compound 9q bearing 4-fluorobenzyl moieties at the R position exhibited the best potencies with an IC50 value of 34.67 ± 3.68 µM. The kinetic evaluations of 9q as the most potent derivatives recorded mix-type inhibition. Compounds 9o and 9q also exhibited potent antioxidant capacity with IC50 values of 38.81 and 40.73 µM, respectively confirming their antioxidant potential. Molecular docking studies of 9q as the most potent derivative were exacuated and it was shown that quinazolinone and acetamide moieties of compound 9q participated in interaction with critical His residues of the binding site. The obtained results demonstrated that the 9q can be considered a suitable pharmacophore to develop potent tyrosinase inhibitors.

Peer Review reports

Introduction

Melanin pigment is produced by the complex melanogenesis process in melanocytes and plays a significant role in determining the color of human skin, eyes, and hair [1]. Melanin also protects humans against the harmful effects of ultraviolet (UV) [2]. On the other hand, excess secretion of melanin from melanocytes leads to dermatologic disorders such as melasma, freckles, post-inflammatory melanoderma vitiligo, and cancer. Also, there are correlations between melanogenesis disorders and neurodegenerative diseases, including Parkinson’s, Alzheimer’s, and Huntington’s diseases [3, 4].

Therefore, more attention has been paid to develop novel agents and reduce the side effects of hyperpigmentation. Tyrosinase (EC.1.14.18.1) is known as the main rate-limiting enzyme that regulates the biosynthesis of melanin production by the conversion of L-tyrosine to L-dopa and then dopaquinone via monophenolase and diphenolase activities [5, 6]. In this context, tyrosinase inhibitors represent key inhibitory agents to overcome the excess production of melanin. A wide variety of standard tyrosinase inhibitors such as kojic acid, tropolone, and hydroquinone are clinically effective. Most of these inhibitors have associated toxic effects and low efficacy problems. Thus, the production of efficient tyrosinase inhibitors is essential for use in the cosmetic, food, medical and agricultural industries [7, 8].

Quinazolinone is a common structural motif with the fused heterocyclic system that is ubiquitous in several pharmaceuticals and natural products. Quinazolin-4(3H)-one exhibited varied ranges of biological properties such as antibacterial, antifungal, anti-inflammatory, anticonvulsant, anticancer, anti-HIV and analgesic activities [9,10,11]. In a recent effort to look for the possible application of quinazolin-4(3H)-one as a tyrosinase inhibitor, 2–4-fluorophenyl-quinazolin-4(3H)-one was reported as tyrosinase inhibitor with IC50 = 120 ± 2 μM against tyrosinase in diphenolase activity. Compound A was found to be a reversible and mixed-type inhibitor in kinetic studies. In silico studies revealed that this compound affected the mass transfer rate by blocking the enzyme catalytic center [12]. Oxoquinazolin-3(4H)-yl)furan-2-carboxamide (compound B) was found to be another potent inhibitor with an IC50 value of 0.028 to 1.775 µM [13]. In 2021, thio-quinazolinone (compound C) demonstrated good potency against tyrosinase and reduced the melanin content in the B16F10 cell line with limited toxicity [14]. Yaru Huang et al. reported the synthesis of derivative D with mix type inhibition pattern. Molecular docking studies showed that quinazolinone ring participated in several H-bound interactions with tyrosinase enzyme [15].

It seems that the quinazolinone scaffold could be categorized as tyrosinase inhibitor and S, or SH groups on the designed pharmacophore, making it possible to interact with residues of the tyrosinase active site. As can be seen in compounds B and C (Fig. 1) increased bulkiness at the 3-position of quinazolinone ring improved the potencies. Recently the effects of different types of substitutions at the 3 position of quinazolinone ring were evaluated and it was shown that isopropyl moiety (compounds E and F, Fig. 1) compared to different aliphatic and aromatic moieties significantly improves the tyrosinase inhibition [16].

Fig. 1
figure 1

Chemical structures of some reported tyrosinase inhibitors and newly designed compound

Full size image

As result in this study, isopropyl moiety as aliphatic and bulk groups were conjugated into the 3-position of quinazolinone compared to previous studies bearing aromatic substitutions in this position. Furthermore, aryl acetamide moieties might be involved in several hydrophobic and hydrophilic interactions with the binding site via occupying the critical cavities of the enzyme. Derivatization was performed on thioquinazolinone moiety using the different aryl acetamides which could affect the tyrosinase inhibition and antioxidant potential.

Hence, the present studies illustrate the design and synthesis of new isopropylquinazolinones with various substituted analogs on acetamide moiety. After successful synthesis and characterization, all compounds were examined for their tyrosinase activity and antioxidant potential. Moreover, the kinetic and molecular docking studies of the most potent derivatives were performed.

Results and discussion

Chemistry

A mixture of isatoic anhydride (compound 1) and appropriate amine (compound 2) was stirred for 30 min at room temperature in water (Scheme 1). The resulting 2-amino-N-isopropylbenzamide (compound 3), carbon disulfide (compound 4), and KOH in ethanol were heated under reflux for 12 h to synthesize 3-isopropyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one (compound 5).

Scheme 1
scheme 1

Synthesis of isopropylquinazolinone derivatives 9a–q

Full size image

On the other hand, to the stiring solution of amine derivatives (compound 6a–q) in DMF at 0 ˚C, chloroacetyl chloride (compound 7) was added dropwise followed by stiring for 5 h at room temperature. After compeletation of the reaction, the mixture was poured into ice water to obtain, 2-chloro-N-phenylnacetamide derivatives (8a–q). Finally, 3-isopropyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one (compound 5), were added to the 2-chloro-N-phenylnacetamide derivatives (8a–q) in DMF in presence of potassium carbonate at room temperature for 4 h. The structure of final products 9a–q was confirmed using NMR and IR spectroscopy as well as elemental analysis.

Mushroom tyrosinase inhibition and structure–activity relationship

All newly synthesized compounds (9a–q) were examined for their inhibitory potentials against the tyrosinase enzyme and the results were presented in Table 1 and the structure–activity relationships (SARs) were constructed. From the experimental data, it appears that all of the synthesized compounds have an inhibitory effect against tyrosinase for the oxidation of L-dopa as compared with kojic acid as the positive control (IC50 = 23.64 ± 2.56 µM).

Table 1 Tyrosinase inhibitory activity of compounds 9a–q
Full size table

The parent compound 9a (% inhibition at 50 µM = 21.64) exhibited weak inhibitory activity against tyrosinase in comparison with the standard kojic acid. The halogen-substituted analogs (9b–e) displayed improvement in the potencies compared to unsubstituted analogs. Amongst, 2-chlorophenyl (9b, % inhibition at 50 µM = 37.97) exhibited the best results as compared to the rest of the halogen-substituted groups. On the other hand, evaluations of para-halogen substituted groups did not present significant differences so that 9d (R = 4-chlorophenyl, % inhibition at 50 µM = 26.86) and 9e (R = 4-bromo-phenyl, % inhibition at 50 µM = 24.77) exhibited similar inhibition at 50 µM. On the other hand, 9f with para-nitro moiety was recorded as the second most active derivative among the electron-withdrawing analogs which could be due to the hydrophilicity of NO2 group as well as its strong electron-withdrawing power.

Furthermore, in most cases, the mono electron-donating substituted analogs (9g–k) showed improvement in the inhibitory potential compared to the unsubstituted derivative, 9a. The best potency among electron-donating derivatives was seen in 9j (R: 4-hydroxyphenyl) and 9g (R: 2-methylphenyl) with 35.48% and 34.62% inhibition at 50 µM. However, changing the position from ortho-methyl to para-methyl reduced the activity in 9h compared to 9g. Also, the replacement of methyl with methoxy did not improve the potency in 9i with just 25.37% inhibition at 50 µM. The activity pattern is a bit the same in the case of the para-ethyl substituted compound (9k) which recorded 20.44% inhibition at 50 µM similar to an unsubstituted derivative. In the case of one electron-donating substitution, it was assumed that increased bulkiness or lipophilicity at the para position is not favorable and the exception in this trend came back to 9j bearing para-hydroxyphenyl.

Compounds 9l-n with dimethyl substitution mostly displayed inferior inhibitory potential compared to the unsubstituted derivative. It seems that increased steric hinder deteriorated the potencies although 9m exhibited 27.31% inhibition at 50 µM. Noteworthy, the replacement of phenyl (9a) with a naphthyl ring (9o) resulted in improved inhibition.

Assessment of phenyl analogs compared with benzyl derivatives recorded interesting results so that derivative 9p (R = benzyl with 29.08% inhibition at 50 µM) revealed better potencies as compared to 9a analogs. Also, 9q bearing 4-fluorobenzyl moiety was discovered to be the most active derivative of the series.

Overall the precise mechanism of action of the isopropylquinazolinones is unknown. However, the increase of benzyl derivatives' potencies compared to the phenyl compounds might indicate better interaction of benzyl analogs with the hydrophobic pocket of the tyrosinase enzyme and the possibility of better rotation of substitutions in the binding pocket of the enzyme. Also, SARs analysis demonstrated mostly, better inhibitory activities of ortho-substituted analogous (9b and 9g) as compared to the para-substituted derivatives (9d and 9h).

Enzyme kinetic studies

According to Fig. 2a, the Lineweaver–Burk plot showed that 9q is a mix-type inhibitor in which the inhibitor may bind to the enzyme whether or not the enzyme has already bound to the substrate. Furthermore, the plot of the slope of the lines versus different concentrations of inhibitor gave an estimate of the inhibition constant (KI) of 13.60 µM (Fig. 2b). Compound 9q also recorded the inhibition constant with the enzyme–substrate complex (KIS) of 87.32 µM (Fig. 2c) [17, 18].

Fig. 2
figure 2

Kinetics of tyrosinase inhibition by 9q. a The Lineweaver–Burk plot in the absence and presence of different concentrations of 9q; b The secondary plot of slopes of the lines vs various concentrations of 9q; c The secondary plot of 1/Vmax vs various concentrations of 9q

Full size image

Inspecting the antioxidant properties of isopropylquinazolinones

In vitro antioxidant activities of the synthesized compounds were determined quantitatively using DPPH radical scavenging assay. DPPH is a stable free radical at room temperature and accepts an electron or hydrogen radical from an antioxidant to become a stable diamagnetic molecule [19]. The results of antioxidant potential are presented in Table 2. These results delineate that the unsubstituted compounds 9a and 9p had no antioxidant capacity while mostly any types of substitutions improved the antioxidant activities. The best potencies came back to 9o bearing naphthyl moiety with an IC50 value of 38.81 µM followed by 9q containing 4-flurobenzyl (IC50 = 40.73 µM). Also, 4-bromophenyl (% inhibition at 100 µM = 41.44) and 4-chloro-phenyl (% inhibition at 100 µM = 42.78) derivatives were other potent antioxidant agents. Similar to previous studies, halogens especially fluorine, increases antioxidant activity [20]. Assessments of electron donating groups showed compound 9n bearing 2,6-dimethyl-phenyl was the most potent agent among electron donating derivatives with 44.38% inhibition at 100 µM.

Table 2 Antioxidant properties of synthesized compounds using DPPH assay
Full size table

Docking study

In the first step, molecular docking validation was performed with the redocking of tropolone as a native ligand inside the tyrosinase. Alignment of the best pose of tropolone in the active site of the enzyme and crystallographic ligand recorded an RMSD value of 0.42 Å (RMSD should be less than 2 Å) which confirms the accuracy of docking. Molecular docking results revealed a fit-well binding pattern of compound 9q with the adaptation of several key interactions with active site residues (Fig. 3).

Fig. 3
figure 3

3D and 2D diagrams of compound 9q within the binding pocket of tyrosinase

Full size image

Numerous significant interactions with catalytic residues were found so that quinazolinone rings interacted through π-π staking interaction with His263 (one of the critical residues of the active site) whereas, the C=O and NH groups of acetamide moieties formed two critical hydrogen bonds with His85 and His244 of target tyrosinase protein. Literature data ensured the importance of these His residues in bonding with tyrosinase inhibitors, which strengthen our docking results.

Conclusions

In summary, in this study, a series of isopropylquinazolinones was developed and evaluated as tyrosinase inhibitors. The SARs was presented by analyzing the impact of varying substitutions on tyrosinase inhibitory potential. The 4-fluorobenzyl-substituted compound 9q displayed the best tyrosinase inhibition of the series. The kinetic studies of the most active compound, 9q, showed that this compound had a mixed mode of inhibition. Also, their antioxidant properties were determined using DPPH assay and SARs analysis of antioxidant capacities showed that the para-halogen substituted compounds displayed better antioxidant activities. The binding conformation of the most potent derivative was determined by a molecular docking study and revealed that structural features of 9q as an active compound play a vital role in the binding interactions of this compound with the enzyme.

Material and methods

Synthesis

A mixture of isatoic anhydride (compound 1, 10 mmol) and appropriate amine (compound 2, 10 mmol) was stirred for 30 min at room temperature in water (20 mL). After completion of the reaction (checked by TLC), the resulting white 2-amino-N-isopropylbenzamide was filtered off and used for the next reaction without further purification. 2-amino-N-isopropylbenzamide (compound 3, 1 mmol), carbon disulfide (compound 4, 1.2 mmol), and KOH (1.5 mmol) in ethanol (5 mL) were heated under reflux for 12 h. After completion of the reaction (checked by TLC), the reaction mixture was poured into cold water which was acidifed with HCL 6N (pH = 5). The precipitates were filtered off, and washed with cold water to obtain the pure 3-isopropyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one (compound 5). To a solution of amine derivatives (compound 6a–q, 1 mmol) in DMF (4 mL) at 0 °C, chloroacetyl chloride (compound 7), was added. The mixture was stirred at room temperature for 5 h and poured into ice water and then filtered to get the obtained solids (8a–q) were then filtered, dried, and recrystallized from ethanol.

A mixture of 3-isopropyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one (compound 5, 1 mmol), 2-chloro-N-phenylnacetamide derivatives (8a–q, 1 mmol) and, potassium carbonate (1.5 mmol) in DMF (5 ml) was stirred at rt for 4 h. Next, the mixture reaction was poured in cold water and the residue was filtrated and purified using recrystallization from ethanol to give 2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)-N-phenylacetamide derivatives (9a–q).

Analytical HPLC evaluation of 9b, 9o, and 9q was performed on a Kanuer HPLC system equipped with UV detectors using an RP column (C18, 5 μm, 150 × 4.6 mm) and solvent acetonitrile and water with flow rate, 1 mL/min; detection, 254 nm; injection volume, 10 μL (Additional file 1: Figs. S1, S2 and S3).

2-((3-Isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)-N-phenylacetamide (9a)

Cream solid; Yield:77%; MP = 190–192 °C; IR (KBr, vmax) 3252 (NH), 3025 (CH Aromatic), 2970(CH Aliphatic), 1660 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 10.39 (s,1H, NH Amide), 8.01 (d, J = 7.90 Hz, 1H, H5), 7.71 (t, J = 7.60 Hz, 1H, H7), 7.61 (d, J = 8.10 Hz, 2H, H2,, H6,), 7.42 (d, J = 8.10 Hz, 1H, H8), 7.38 (t, J = 7.50 Hz, 1H, H6), 7.29 (t, J = 7.80 Hz, 2H, H3, H5), 7.03 (t, J = 7.30 Hz, 1H, H4), 4.75–4.40 (m, 1H, CH Isopropyl), 4.17 (s, 2H, CH2), 1.59 (d, J = 6.70 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.2, 161.3, 156.6, 146.6, 139.5, 134.9, 129.2, 126.6, 126.3, 125.8, 123.8, 120.3, 119.5; ESI–MS (C19H19N3O2S): calculated m/z 353.12 [M + H]+, observed m/z 353.19[M + H]+; Anal. Calcd: C19H19N3O2S; C, 64.57; H, 5.42; N, 11.89; Found; C, 64.69; H, 5.57; N, 12.02.

N-(2-chlorophenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9b)

Brown solid; Yield:78%; MP = 207–209 °C; IR (KBr, vmax) 3357 (NH), 3070 (CH Aromatic), 2980 (CH Aliphatic), 1677 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 9.86 (s,1H, NH Amide), 8.03 (d, J = 7.90 Hz, 1H, H5), 7.80–7.69 (m, 2H, H7, H6), 7.50 (d, J = 8.10 Hz, 1H, H8), 7.45 (d, J = 8.00 Hz, 1H, H3), 7.39 (t, J = 7.50 Hz, 1H, H6), 7.28 (t, J = 7.70 Hz, 1H, H5), 7.14 (t, J = 7.60 Hz, 1H, H4),4.83–4.54 (m, 1H, CH Isopropyl), 4.27 (s, 2H, CH2), 1.59 (d, J = 6.50 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.8, 161.3, 156.4, 146.6,135.2, 134.8, 129.9, 127.9, 126.6, 126.3, 126.2, 126.0, 125.8, 120.3, 37.0, 19.6; ESI–MS (C19H18ClN3O2S): calculated m/z 387.08 [M + H]+, observed m/z 387.13 [M + H]+; Anal. Calcd: C19H18ClN3O2S; C, 58.83; H, 4.68; N, 10.83; Found; C, 59.13; H, 4.85; N, 11.01.

N-(3-chlorophenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9c)

Brown solid; Yield:74%; MP = 203–205 °C; IR (KBr, vmax) 3363 (NH), 3070 (CH Aromatic), 2980 (CH Aliphatic), 1681 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 10.60 (s,1H, NH Amide), 8.01 (d, J = 8.20 Hz, 1H, H5), 7.81 (s, 1H, H2), 7.71 (t, J = 7.60 Hz, 1H, H7), 7.48 (d, J = 8.50 Hz, 1H, H8),7.40–7.36 (m, 2H, H6, H6), 7.34 (t, J = 8.00 Hz, 1H, H5), 7.10 (d, J = 8.50 Hz, 1H, H4), 4.74–4.54 (m, 1H, CH Isopropyl), 4.18 (s, 2H, CH2), 1.59 (d, J = 6.50 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.7, 161.3, 156.5, 146.6, 140.9, 134.9, 133.5, 130.9, 126.6, 126.3, 125.8, 123.5, 120.3, 119.0, 117.9, 37.7, 19.6; ESI–MS (C19H18ClN3O2S): calculated m/z 387.08 [M + H]+, observed m/z 387.17 [M + H]+; Anal. Calcd: C19H18ClN3O2S; C, 58.83; H, 4.68; N, 10.83; Found; C, 59.03; H, 4.81; N, 10.98.

N-(4-chlorophenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9d)

Brown solid; Yield:79%; MP = 211–213 °C; IR (KBr, vmax) 3378 (NH), 3065 (CH Aromatic), 2990 (CH Aliphatic), 1703 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 10.54 (s,1H, NH Amide), 8.01 (d, J = 8.00 Hz, 1H, H5), 7.70 (t, J = 7.60 Hz, 1H, H7), 7.64 (d, J = 8.50 Hz, 2H, H2, H6),7.41–7.36 (m, 2H, H8, H6), 7.35 (d, J = 8.50 Hz, 2H, H3, H5), 4.81–4.54 (m, 1H, CH Isopropyl), 4.17 (s, 2H, CH2), 1.58 (d, J = 6.60 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.4, 161.3, 156.5, 146.6, 138.4, 134.9, 129.1, 127.4, 126.6, 126.3, 125.8, 121.0, 120.3, 37.7, 19.6; ESI–MS (C19H18ClN3O2S): calculated m/z 387.08 [M + H]+, observed m/z 387.21 [M + H]+; Anal. Calcd: C19H18ClN3O2S; C, 58.83; H, 4.68; N, 10.83; Found; C, 59.11; H, 4.89; N, 10.98.

N-(4-bromophenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9e)

Brown solid; Yield: 84%; MP = 203–205 °C; IR (KBr, vmax) 3378 (NH), 3020 (CH Aromatic), 2885 (CH Aliphatic), 1661 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 10.54 (s,1H, NH Amide), 8.01 (d, J = 7.90 Hz, 1H, H5), 7.70 (t, J = 7.60 Hz, 1H, H7), 7.59 (d, J = 8.10 Hz, 2H, H2, H6), 7.49–7.44 (m, 2H, H8, H6), 7.40–7.34 (m, 2H, H3, H5), 4.75–4.52 (m, 1H, CH Isopropyl), 4.17 (s, 2H, CH2), 1.58 (d, J = 6.70 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.5, 161.3, 156.5, 146.6, 138.8, 134.9, 132.0, 126.6, 126.3, 125.8, 121.4, 120.3, 115.4, 37.8, 19.6; ESI–MS (C19H18BrN3O2S): calculated m/z 431.03 [M + H]+, observed m/z 431.09 [M + H]+; Anal. Calcd: C19H18BrN3O2S; C, 52.78; H, 4.20; N, 9.72; Found; C, 52.91; H, 4.40; N, 9.97.

2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)-N-(4-nitrophenyl)acetamide (9f)

Brown solid; Yield:81%; MP = 216–218 °C; IR (KBr, vmax) 3343(NH), 3040(CH Aromatic), 2980(CH Aliphatic), 1674(C=O), 1560–1355(NO2) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 11.03 (s,1H, NH Amide), 8.22 (d, J = 7.50 Hz, 2H, H3, H5), 8.00 (d, J = 7.90 Hz, 1H, H5), 7.87 (d, J = 8.10 Hz, 2H, H2, H6), 7.68 (t, J = 7.60 Hz, 1H, H7), 7.37 (t, J = 7.20 Hz, 1H, H6), 7.37 (d, J = 7.20 Hz, 1H, H8), 4.84–4.43 (m, 1H, CH Isopropyl), 4.22 (s, 2H, CH2), 1.60 (d, J = 6.10 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 167.5, 161.3, 156.4, 146.5, 145.6, 142.7, 135.0, 126.6, 126.3, 125.7, 125. 5, 125.4, 119.2, 37.8, 19.6; ESI–MS (C19H18N4O4S): calculated m/z 398.10 [M + H]+, observed m/z 398.28 [M + H]+; Anal. Calcd: C19H18N4O4S; C, 57.27; H, 4.55; N, 14.06; Found; C, 57.43; H, 4.81; N, 14.25.

2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)-N-(o-tolyl)acetamide (9g)

Cream solid; Yield:76%; MP = 196–198 °C; IR (KBr, vmax) 3238 (NH), 3035 (CH Aromatic), 2965 (CH Aliphatic), 1682 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 9.69 (s,1H, NH Amide), 8.04 (d, J = 7.90 Hz, 1H, H5), 7.75 (t, J = 7.60 Hz, 1H, H7), 7.50 (d, J = 8.10 Hz, 1H, H8), 7.41 (t, J = 7.50 Hz, 1H, H6), 7.36 (d, J = 7.80 Hz, 1H, H3), 7.18 (d, J = 7.30 Hz, 1H, H6), 7.13 (t, J = 7.50 Hz, 1H, H5), 7.06 (t, J = 7.30 Hz, 1H, H4), 4.81–4.57 (m, 1H, CH Isopropyl), 4.22 (s, 2H, CH2), 2.18 (s, 3H, CH3), 1.59 (d, J = 6.50 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.2, 161.3, 156.6, 146.6, 136.6, 134.9, 132.3, 130.7, 126.6, 126.4, 126.3, 125.9, 125.8, 125.4, 120.4, 34.0, 19.6, 18.2; ESI–MS (C20H21N3O2S): calculated m/z 387.08 [M + H]+, observed m/z 387.13 [M + H]+; Anal. Calcd: C20H21N3O2S; C, 65.37; H, 5.76; N, 11.44; Found; C, 65.52; H, 5.91; N, 11.67.

2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)-N-(p-tolyl)acetamide (9h)

Cream solid; Yield:76%; MP = 199–201 °C; IR (KBr, vmax) 3400 (NH), 3020(CH Aromatic), 2975(CH Aliphatic) 1701(C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 10.44 (s,1H, NH Amide), 8.01 (d, J = 7.90 Hz, 1H, H5), 7.71 (t, J = 7.60 Hz, 1H, H7), 7.50 (d, J = 8.30 Hz, 2H, H2, H6), 7.42 (d, J = 8.10 Hz, 1H, H8), 7.38 (t, J = 7.50 Hz, 1H, H6), 7.09 (d, J = 8.10 Hz, 2H, H3, H5), 4.75–4.57 (m, 1H, CH Isopropyl), 4.17 (s, 2H, CH2), 2.22 (s, 3H, CH3), 1.59 (d, J = 6.60 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.0, 161.3, 156.6, 146.6, 137.0, 134.9, 132.7, 129.5, 126.5, 126.2, 125.9, 120.3, 119.5, 37.7, 20.8, 19.6; ESI–MS (C20H21N3O2S): calculated m/z 367.14 [M + H]+, observed m/z 367.28 [M + H]+; Anal. Calcd: C20H21N3O2S; C, 65.37; H, 5.76; N, 11.44; Found; C, 65.51; H, 5.97; N, 11.59.

2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)-N-(4-methoxyphenyl)acetamide (9i)

Cream solid; Yield:88%; MP = 205–207 °C; IR (KBr, vmax) 3253 (NH), 3030 (CH Aromatic), 2975(CH Aliphatic), 1661(C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 10.25 (s,1H, NH Amide), 8.02 (d, J = 7.90 Hz, 1H, H5), 7.72 (t, J = 7.60 Hz, 1H, H7), 7.51 (d, J = 8.20 Hz, 2H, H2, H6),7.44 (d, J = 8.10 Hz, 1H, H8), 7.39 (t, J = 7.60 Hz, 1H, H6), 6.87 (d, J = 8.20 Hz, 2H, H3, H5), 4.83–4.51 (m, 1H, CH Isopropyl), 4.14 (s, 2H, CH2), 3.70 (s, 3H, CH3), 1.59 (d, J = 6.50 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 165.7, 161.3, 156.6, 155.7, 146.6, 134.9, 132.6, 126.6, 126.3, 125.9, 121.1, 120.3, 114.3, 55.5, 37.7, 19.6; ESI–MS (C20H21N3O3S): calculated m/z 383.13 [M + H]+, observed m/z 383.29 [M + H]+; Anal. Calcd: C20H21N3O3S; C, 62.64; H, 5.52; N, 10.96; Found; C, 62.82; H, 5.75; N, 11.13.

N-(4-hydroxyphenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide(9j)

Cream solid; Yield:77%; MP = 193–195 °C; IR (KBr, vmax) 3295 (NH), 3075(CH Aromatic), 2970(CH Aliphatic), 1675 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 11.98 (s,1H, OH), 10.25 (s,1H, NH Amide), 8.03 (d, J = 7.70 Hz, 1H, H5), 7.74 (t, J = 7.50 Hz, 1H, H7), 7.52(d, J = 8.00 Hz, 2H, H2, H6),7.43 (d, J = 7.90 Hz, 1H, H8), 7.39 (t, J = 7.50 Hz, 1H, H6), 6.88 (d, J = 8.10 Hz, 2H, H3, H5), 4.67 (m, 1H, CHIsopropyl), 4.25 (s, 2H, CH2), 1.60 (d, J = 6.50 Hz, 3H, CH3) 1.59 (d, J = 6.40 Hz, 3H, CH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 165.5, 161.4, 156.7, 155.8, 147.6, 134.9, 132.6, 127.6, 127.3, 126.8, 122.1, 120.5, 115.4, 38.7, 19.6; ESI–MS (C19H19N3O3S): calculated m/z 369.11 [M + H]+, observed m/z 370.11 [M + H]+; Anal. Calcd: C19H19N3O3S; C, 61.77; H, 5.18; N, 11.37; Found; C, 62.05; H, 5.81; N, 11.17.

N-(4-ethylphenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9k)

Cream solid; Yield:81%; MP = 195–197 °C; IR (KBr, vmax) 3401 (NH), 3065(CH Aromatic), 2950(CH Aliphatic), 1670 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 10.44 (s,1H, NH Amide), 8.01 (d, J = 7.40 Hz, 1H, H5), 7.72 (t, J = 7.60 Hz, 1H, H7), 7.52 (d, J = 8.30 Hz, 2H, H2, H6), 7.43 (d, J = 8.20 Hz, 1H, H8), 7.39 (t, J = 7.60 Hz, 1H, H6), 7.12 (d, J = 8.10 Hz, 2H, H3, H5), 4.76–4.59 (m, 1H, CH Isopropyl), 4.17 (s, 2H, CH2), 2.52 (q, 2H, CH2 Ethyl), 1.58 (d, J = 6.60 Hz, 6H, 2xCH3), 1.13 (t, 3H, CH3 Ethyl) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.0, 161.3, 156.6, 146.6, 139.1, 137.2, 134.9, 128.3, 126.5, 126.3, 125.9, 120.3, 119.6, 37.7, 28.0, 19.6, 16.1. ESI–MS (C21H23N3O2S): calculated m/z 381.15 [M + H]+, observed m/z 381.27 [M + H]+; Anal. Calcd: C21H23N3O2S; C, 66.12; H, 6.08; N, 11.01; Found C, 66.37; H, 6.24; N, 11.35.

N-(2,3-dimethylphenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9l)

Brown solid; Yield:69%; MP = 217–219 °C; IR (KBr, vmax) 3371 (NH), 3040 (CH Aromatic), 2985 (CH Aliphatic), 1669 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 9.86 (s, 1H, NH Amide), 8.03 (d, J = 7.90 Hz, 1H, H5), 7.75 (t, J = 7.20 Hz, 1H, H7), 7.51 (d, J = 8.20 Hz, 1H, H8), 7.41 (t, J = 7.50 Hz, 1H, H6), 7.09 (d, J = 7.50 Hz, 1H, H6),7.03–6.95 (m, 2H, H4, H5), 4.75–4.61 (m, 1H, CH Isopropyl), 4.21 (s, 2H, CH2), 2.20 (s, 3H, CH3), 2.04 (s, 3H, CH3), 1.59 (d, J = 6.60 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 166.2, 161.4, 156.6, 146.7, 137.4, 136.4, 134.9, 131.8, 127.5, 126.6, 126.3, 126.0, 125.6, 123.9, 120.3, 37.0, 20.5, 19.6, 14.5; ESI–MS (C21H23N3O2S): calculated m/z 381.15 [M + H]+, observed m/z 381.24 [M + H]+; Anal. Calcd: C21H23N3O2S; C, 66.12; H, 6.08; N, 11.01; Found; C, 66.33; H, 6.27; N, 11.21.

N-(2,4-dimethylphenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9m)

Brown solid; Yield: 69%; MP = 222–225 °C; IR (KBr, vmax) 3376 (NH), 3045 (CH Aromatic), 2995 (CH Aliphatic), 1674 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 9.57 (s,1H, NH Amide), 8.04 (d, J = 7.90 Hz, 1H, H5), 7.77 (t, J = 7.60 Hz, 1H, H7), 7.53 (d, J = 8.80 Hz, 1H, H6), 7.42 (t, J = 7.50 Hz, 1H, H6), 7.09–6.98 (m, 3H, H8, H3, H5), 4.81–4.60 (m, 1H, CH Isopropyl), 4.23 (s, 2H, CH2), 3.32 (s, 3H, CH3), 2.09 (s, 3H, CH3), 1.60 (d, J = 6.60 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 165.7, 161.4, 156.5, 146.7, 135.7, 135.3, 134.9, 128.0, 127.0, 126.6, 126.3, 126.0, 34.4, 19.6, 18.5; ESI–MS (C21H23N3O2S): calculated m/z 381.15 [M + H]+, observed m/z 381.31 [M + H]+; Anal. Calcd: C21H23N3O2S; C, 66.12; H, 6.08; N, 11.01; Found; C, 66.28; H, 6.34; N, 11.17.

N-(2,6-dimethylphenyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9n)

Cream solid; Yield:68%; MP = 215–217 °C; IR (KBr, vmax) 3235 (NH), 3030 (CH Aromatic), 2970 (CH Aliphatic), 1684 (C=O) Cm−1; 1H NMR (500 MHz,DMSO-d6) δ 9.57 (s,1H, NH Amide), 8.04 (d, J = 8.00 Hz, 1H, H5), 7.77 (t, J = 7.70 Hz, 1H, H7), 7.53 (d, J = 8.20 Hz, 1H, H8), 7.42 (t, J = 7.50 Hz, 1H, H6), 7.05–7.00 (m,3H, H4, H3, H5), 4.79–4.64 (m, 1H, CHIsopropyl), 4.23 (s, 2H, CH2), 2.09 (s, 6H, 2 × CH3), 1.60 (d, J = 6.60 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 165.7, 161.4, 156.5,146.7, 135.7, 135.3, 134.9,128.0, 127.0, 126.6, 126.3, 126.0, 120.4, 36.4, 19.6, 18.5; ESI–MS (C21H23N3O2S): calculated m/z 381.15 [M + H]+, observed m/z 381.24 [M + H]+; Anal. Calcd: C21H23N3O2S; C, 66.12; H, 6.08; N, 11.01; Found; C, 66.23; H, 6.29; N, 11.26.

2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)-N-(naphthalen-2-yl)acetamide (9o)

Cream solid; Yield:65%; MP = 217–219 °C; IR (KBr, vmax) 3291 (NH), 3065 (CH Aromatic), 2980(CH Aliphatic), 1675 (C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 10.36 (s,1H, NHAmide), 8.17 (d, J = 7.8 Hz, 1H, H8), 8.05 (d, J = 7.80 Hz, 1H, H5), 7.86 (t, J = 7.60 Hz, 1H, H7), 7.84–7.80 (m, 1H, H8), 7.75 (t, J = 7.50 Hz, 1H, H6), 7.64 (d, J = 7.80 Hz, 1H, H7), 7.61–7.56 (m, 2H, H3, H6), 7.46 (t, J = 7.50 Hz, 1H, H4), 7.13 (t, J = 7.60 Hz, 1H, H5), 4.25–4.12 (m, 1H, CH Isopropyl), 4.01 (s, 2H, CH2), 0.80 (d, J = 6.70 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 165.9, 164.2, 161.2, 156.8, 147.7, 135.8, 135.5, 134.5, 132.2, 132.0, 131.2, 128.8, 127.0, 126.4, 126.3, 121.2, 121.2, 115.9, 115.7, 37.4, 13.7; ESI–MS (C23H21N3O2S): calculated m/z 403.14 [M + H]+, observed m/z 403.27 [M + H]+; Anal. Calcd: C23H21N3O2S; C, 68.46; H, 5.25; N, 10.41; Found; C, 68.65; H, 5.42; N, 10.60.

N-benzyl-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9p)

Cream solid; Yield:81%; MP = 194–196 °C; IR (KBr, vmax) 3264 (NH), 3025(CH Aromatic), 2960 (CH Aliphatic),1662(C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 8.73 (t, J = 6.20 Hz, 1H, NH Amide), 8.03 (d, J = 8.10 Hz, 1H, H5), 7.73 (t, J = 7.60 Hz, 1H, H7), 7.45–7.38 (m, 2H, H8, H6), 7.24–7.18 (m, 5H, H Benzyl), 4.77–4.56 (m, 1H, CH Isopropyl), 4.32 (d, J = 5.90 Hz, 2H, CH2 Benzyl), 4.05 (s, 2H, CH2), 1.58 (d, J = 6.50 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 167.2, 161.4, 156.5, 146.6, 139.6, 134.8, 128.6, 127.5, 127.5, 127.1, 126.5, 126.2, 126.1, 120.3, 43.0, 36.5, 19.6; ESI–MS (C20H21N3O2S): calculated m/z 367.14 [M + H]+, observed m/z 367.26 [M + H]+; Anal. Calcd: C20H21N3O2S; C, 65.37; H, 5.76; N, 11.44; Found; C, 65.49; H, 5.98; N, 11.63.

N-(4-fluorobenzyl)-2-((3-isopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide (9q)

Cream solid; Yield:76%; MP = 224–226 °C; IR (KBr, vmax) 3314 (NH), 3050(CH Aromatic), 2960(CHAliphatic), 1671(C=O) Cm−1; 1H NMR (500 MHz, DMSO-d6) δ 8.83 (t, J = 6.10 Hz, 1H, NH Amide), 8.02 (d, J = 8.00 Hz, 1H, H5), 7.73 (t, J = 7.60 Hz, 1H, H7), 7.41 (t, J = 7.50 Hz, 1H, H6), 7.36 (d, J = 8.10 Hz, 1H, H8), 7.29–7.23 (m, 2H, H2, H6), 7.04–6.97 (m, 2H, H3, H5), 4.72–4.58 (m, 1H, CH Isopropyl), 4.28 (d, J = 5.90 Hz, 2H, CH2 Benzyl), 4.03 (s, 2H, CH2), 1.56 (d, J = 6.50 Hz, 6H, 2xCH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 167.2, 162.5, 161.4, 160.5, 156.5, 146.6, 135.9, 135.8, 134.8, 129.5, 129.5, 126.5, 126.2, 126.0, 120.3, 115.3, 115.2, 42.2, 36.5, 19.6; ESI–MS (C20H20FN3O2S): calculated m/z 385.13 [M + H]+, observed m/z 385.26 [M + H]+; Anal. Calcd: C20H20FN3O2S; C, 62.32; H, 5.23; N, 10.90; Found; C, 62.54; H, 5.37; N, 11.07.

Screening of tyrosinase inhibitory activity

Tyrosinase inhibitory activity was determined based on the previously described procedure with a slight modification [3, 21]. In brief, the test reaction mixture comprised 10 µL of each derivative, and 10 µL of mushroom tyrosinase (500 units; Sigma-Aldrich, St Louis, MO, USA) in 160 potassium phosphate buffer (pH = 6.8). The reaction mixture was incubated at 37 °C for 20 min and then 20 µL of L-Dopa (0.5 mmol/L) was added to each well, and the absorption was measured at 475 nm. The absorbance of the same mixture without tyrosinase was used as the control. Kojic acid was used as a positive control. The optical density of the inhibition in the control was considered to represent 100%. The data are expressed as mean percentages and the results were repeated in triplicate.

Enzyme kinetic studies

The mode of inhibition of the most active compound 9q identified with the lowest IC50, was investigated against tyrosinase activity with different concentrations of L-Dopa (0.1.5 mM) as substrate in the absence and presence of 9q at different concentrations (10, 20, 30, 40 and 50 µM). A Lineweaver–Burk plot was generated to identify the type of inhibition and the Michaelis–Menten constant (Km) value was determined from the plot between the reciprocal of the substrate concentration (1/[S]) and reciprocal of enzyme rate (1/V) over various inhibitor concentrations.

Antioxidant activities

The DPPH antioxidant potencies of all derivatives were performed according to previously published articles [22].

Molecular docking

The molecular docking studies were performed using the Maestro Molecular Modeling platform (version 10.5) by Schrödinger, LLC. The X-ray crystal structure of the receptor (PDB ID: 2Y9X) was extracted from the PDB database. The protein is then prepared using a protein preparation wizard, the co-crystallized ligands and all water molecules were removed [23], the missing side chains and loops were filled using the prime tool, and PROPKA assigned H-bonds at pH: 7.4. To prepare the ligands, the 2D structures of the ligands were drawn in ChemDraw and converted into SDF files and subjected to ligprep module [24]. Ligands were prepared by OPLS_2005 force field using EPIK. The grid box was generated for each binding site using entries with a box size of 20 Å, the derivative was docked on binding sites using induced-fit docking, reporting 10 poses per ligand to form the final complex.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in the Worldwide Protein Data Bank (wwPDB) repository; (https://www.rcsb.org/structure/2y9x) with PDB https://doi.org/10.2210/pdb2Y9X/pdb.

References

  1. Sepehri N, Iraji A, Yavari A, Asgari MS, Zamani S, Hosseini S, Bahadorikhalili S, Pirhadi S, Larijani B, Khoshneviszadeh M. The natural-based optimization of kojic acid conjugated to different thio-quinazolinones as potential anti-melanogenesis agents with tyrosinase inhibitory activity. Bioorg Med Chem. 2021;36: 116044.

    Article  CAS  PubMed  Google Scholar 

  2. Hosseinpoor H, Farid SM, Iraji A, Askari S, Edraki N, Hosseini S, Jamshidzadeh A, Larijani B, Attarroshan M, Pirhadi S. Anti-melanogenesis and anti-tyrosinase properties of aryl-substituted acetamides of phenoxy methyl triazole conjugated with thiosemicarbazide: design, synthesis and biological evaluations. Bioorg Chem. 2021;114: 104979.

    Article  CAS  PubMed  Google Scholar 

  3. Iraji A, Adelpour T, Edraki N, Khoshneviszadeh M, Miri R, Khoshneviszadeh M. Synthesis, biological evaluation and molecular docking analysis of vaniline–benzylidenehydrazine hybrids as potent tyrosinase inhibitors. BMC Chem. 2020;14(1):28.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Karimian S, Kazemi F, Attarroshan M, Gholampour M, Hemmati S, Sakhteman A, Behzadipour Y, Kabiri M, Iraji A, Khoshneviszadeh M. Design, synthesis, and biological evaluation of symmetrical azine derivatives as novel tyrosinase inhibitors. BMC Chem. 2021;15(1):54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Karimian S, Kazemi F, Attarroshan M, Gholampour M, Hemmati S, Sakhteman A, Behzadipour Y, Kabiri M, Iraji A, Khoshneviszadeh M. Design, synthesis, and biological evaluation of symmetrical azine derivatives as novel tyrosinase inhibitors. BMC Chem. 2021;15(1):1–11.

    Article  Google Scholar 

  6. Sepehri N, Khoshneviszadeh M, Farid SM, Moayedi SS, Asgari MS, Moazzam A, Hosseini S, Adibi H, Larijani B, Pirhadi S. Design, synthesis, biological evaluation, and molecular docking study of thioxo-2, 3-dihydroquinazolinone derivative as tyrosinase inhibitors. J Mol Struct. 2022;1253: 132283.

    Article  CAS  Google Scholar 

  7. Hosseinpoor H, Iraji A, Edraki N, Pirhadi S, Attarroshan M, Khoshneviszadeh M, Khoshneviszadeh M. A series of benzylidenes linked to hydrazine-1-carbothioamide as tyrosinase inhibitors: synthesis, biological evaluation and structure–activity relationship. Chem Biodivers. 2020;17(8): e2000285.

    Article  CAS  PubMed  Google Scholar 

  8. Iraji A, Sheikhi N, Attarroshan M, Ardani GRS, Kabiri M, Bafghi AN, Kobarfard F, Rezaei Z, Khoshneviszadeh M, Foroumadi A. Design, synthesis, spectroscopic characterization, in vitro tyrosinase inhibition, antioxidant evaluation, in silico and kinetic studies of substituted indole-carbohydrazides. Bioorgan Chem. 2022. https://doi.org/10.1016/j.bioorg.2022.106140.

    Article  Google Scholar 

  9. FZ M, HH M, Synthesis and biological evaluation studies of novel quinazolinone derivatives as antibacterial and anti-inflammatory agents, Saudi Pharm J SPJ. 2014; 22(2): 157–62.

  10. Ding PP, Gao M, Mao BB, Cao SL, Liu CH, Yang CR, Li ZF, Liao J, Zhao H, Li Z, Li J, Wang H, Xu X. Synthesis and biological evaluation of quinazolin-4(3H)-one derivatives bearing dithiocarbamate side chain at C2-position as potential antitumor agents. Eur J Med Chem. 2016;108:364–73.

    Article  CAS  PubMed  Google Scholar 

  11. Mirgany TO, Abdalla AN, Arifuzzaman M, Motiur Rahman AFM, Al-Salem HS. Quinazolin-4(3H)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity. J Enzyme Inhibit Med Chem. 2021;36(1):2055–67.

    Article  CAS  Google Scholar 

  12. Wang R, Chai W-M, Yang Q, Wei M-K, Peng Y. 2-(4-Fluorophenyl)-quinazolin-4(3H)-one as a novel tyrosinase inhibitor: synthesis, inhibitory activity, and mechanism. Bioorg Med Chem. 2016;24(19):4620–5.

    Article  CAS  PubMed  Google Scholar 

  13. Dige NC, Mahajan PG, Raza H, Hassan M, Vanjare BD, Hong H, Hwan Lee K, Latip J, Seo S-Y. Ultrasound mediated efficient synthesis of new 4-oxoquinazolin-3(4H)-yl)furan-2-carboxamides as potent tyrosinase inhibitors: mechanistic approach through chemoinformatics and molecular docking studies. Bioorgan Chem. 2019;92: 103201.

    Article  CAS  Google Scholar 

  14. Sepehri N, Iraji A, Yavari A, Asgari MS, Zamani S, Hosseini S, Bahadorikhalili S, Pirhadi S, Larijani B, Khoshneviszadeh M, Hamedifar H, Mahdavi M, Khoshneviszadeh M. The natural-based optimization of kojic acid conjugated to different thio-quinazolinones as potential anti-melanogenesis agents with tyrosinase inhibitory activity. Bioorg Med Chem. 2021;36: 116044.

    Article  CAS  PubMed  Google Scholar 

  15. Huang Y, Yang J, Chi Y, Gong C, Yang H, Zeng F, Gao F, Hua X, Wang Z. Newly designed quinazolinone derivatives as novel tyrosinase inhibitor: synthesis, inhibitory activity, and mechanism. Molecules. 2022;27(17):5558.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sepehri N, Khoshneviszadeh M, Farid SM, Moayedi SS, Asgari MS, Moazzam A, Hosseini S, Adibi H, Larijani B, Pirhadi S, Attarroshan M, Sakhteman A, Kabiri M, Hamedifar H, Iraji A, Mahdavi M. Design, synthesis, biological evaluation, and molecular docking study of thioxo-2,3-dihydroquinazolinone derivative as tyrosinase inhibitors. J Mol Struct. 2022;1253: 132283.

    Article  CAS  Google Scholar 

  17. Cao S, Wang D, Cheng R, Shi W, Zhang Q, Zeng H, Chen J. Modulation of the lipophilicity and molecular size of thiosemicarbazone inhibitors to regulate tyrosinase activity. Spectrochim Acta Part A Mol Biomol Spectrosc. 2022;281: 121590.

    Article  CAS  Google Scholar 

  18. Hałdys K, Goldeman W, Anger-Góra N, Rossowska J, Latajka R. Monosubstituted acetophenone thiosemicarbazones as potent inhibitors of tyrosinase: synthesis, inhibitory studies, and molecular docking. Pharmaceuticals. 2021;14(1):74.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Iraji A, Firuzi O, Khoshneviszadeh M, Nadri H, Edraki N, Miri R. Synthesis and structure–activity relationship study of multi-target triazine derivatives as innovative candidates for treatment of Alzheimer’s disease. Bioorg Chem. 2018;77:223–35.

    Article  CAS  PubMed  Google Scholar 

  20. Haider K, Haider MR, Neha K, Yar MS. Free radical scavengers: an overview on heterocyclic advances and medicinal prospects. Eur J Med Chem. 2020;204: 112607.

    Article  CAS  PubMed  Google Scholar 

  21. Alizadeh N, Sayahi MH, Iraji A, Yazzaf R, Moazzam A, Mobaraki K, Adib M, Attarroshan M, Larijani B, Rastegar H. Evaluating the effects of disubstituted 3-hydroxy-1H-pyrrol-2 (5H)-one analog as novel tyrosinase inhibitors. Bioorg Chem. 2022;126: 105876.

    Article  CAS  PubMed  Google Scholar 

  22. Mardani M, Afra SM, Tanideh N, Tadbir AA, Modarresi F, Koohi-Hosseinabadi O, Iraji A, Sepehrimanesh M. Hydroalcoholic extract of Carum carvi L. in oral mucositis: a clinical trial in male golden hamsters. Oral Dis. 2016;22(1):39–45.

    Article  CAS  PubMed  Google Scholar 

  23. Pedrood K, Rezaei Z, Khavaninzadeh K, Larijani B, Iraji A, Hosseini S, Mojtabavi S, Dianatpour M, Rastegar H, Faramarzi MA, Hamedifar H, Hajimiri MH, Mahdavi M. Design, synthesis, and molecular docking studies of diphenylquinoxaline-6-carbohydrazide hybrids as potent α-glucosidase inhibitors. BMC Chem. 2022;16(1):57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zarenezhad E, Montazer MN, Tabatabaee M, Irajie C, Iraji A. New solid phase methodology for the synthesis of biscoumarin derivatives: experimental and in silico approaches. BMC Chem. 2022;16(1):53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

The authors wish to thank the support of the Vice-Chancellor for Research of Shiraz University of Medical Sciences (grant number: IR.SUMS.REC.1401.510). This study was part of the M.D. thesis of Majid Heydari. The funder had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Authors and Affiliations

  1. Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Arshia Hashemi, Seyed Esmaeil Sadat-Ebrahimi & Mohammad Ali Daneshmehr

  2. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Milad Noori, Navid Dastyafteh, Bagher Larijani & Mohammad Mahdavi

  3. Molecular Dermatology Research Center and Department of Dermatology, Shiraz University of Medical Sciences, Shiraz, Iran

    Negin Fazelzadeh Haghighi

  4. Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Milad Noori, Katayoun Mehrpour & Aida Iraji

  5. Central Research Laboratory, Shiraz University of Medical Sciences, Shiraz, Iran

    Katayoun Mehrpour & Aida Iraji

  6. Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    Elahe Sattarinezhad

  7. Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

    Fatemeh Jalali Zafrei

  8. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

    Cambyz Irajie

  9. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

    Majid Heydari

Authors
  1. Arshia Hashemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Milad Noori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Navid Dastyafteh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyed Esmaeil Sadat-Ebrahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Negin Fazelzadeh Haghighi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katayoun Mehrpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elahe Sattarinezhad
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fatemeh Jalali Zafrei
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cambyz Irajie
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mohammad Ali Daneshmehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Majid Heydari
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Bagher Larijani
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Aida Iraji
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mohammad Mahdavi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A.H., M.N., N.D., S.E.S.E., F.J.Z., M.A.D and. M.M synthesized compounds and contributed to the design and characterization of compounds. K.M, M.H. E.S and B.L. performed the biological assay. N.F.H. C.I and A.I. performed in silico study and contributed to the preparation of the manuscript. AI. supervised the biological tests. M.M. supervised all phases of the study. All authors read and approved the article.

Corresponding authors

Correspondence to Aida Iraji or Mohammad Mahdavi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure. S1

. HPLC results of 9a. Figure S2. HPLC results of 9n. Figure S3. HPLC results of 9p. Figure S4. 1HNMR spectrum of compound 9a. Figure S5. 13CNMR spectrum of compound 9a. Figure S6. 1HNMR spectrum of compound 9b. Figure S7. 13CNMR spectrum of compound 9b. Figure S8. 1HNMR spectrum of compound 9c. Figure S9. 13CNMR spectrum of compound 9c. Figure S10. 1HNMR spectrum of compound 9d. Figure S11. 13CNMR spectrum of compound 9d. Figure S12. 1HNMR spectrum of compound 9e. Figure S13. 13CNMR spectrum of compound 9e. Figure S14. 1HNMR spectrum of compound 9f. Figure S15. 13CNMR spectrum of compound 9f. Figure S16. 1HNMR spectrum of compound 9g. Figure S17. 13CNMR spectrum of compound 9g. Figure S18. 1HNMR spectrum of compound 9h. Figure S19. 13CNMR spectrum of compound 9h. Figure S20. 1HNMR spectrum of compound 9i. Figure S21. 13CNMR spectrum of compound 9i. Figure S22. 1HNMR spectrum of compound 9j. Figure S23. 13CNMR spectrum of compound 9j. Figure S24. 1HNMR spectrum of compound 9k. Figure S25. 13CNMR spectrum of compound 9k. Figure S26. 1HNMR spectrum of compound 9l. Figure S27. 13CNMR spectrum of compound 9l. Figure S28. 1HNMR spectrum of compound 9m. Figure S29. 13CNMR spectrum of compound 9m. Figure S30. 1HNMR spectrum of compound 9n. Figure S31. 13CNMR spectrum of compound 9n. Figure S32. 1HNMR spectrum of compound 9o. Figure S33. 13CNMR spectrum of compound 9o. Figure S34. 1HNMR spectrum of compound 9p. Figure S35. 13CNMR spectrum of compound 9p. Figure S36. 1HNMR spectrum of compound 9q. Figure S37. 13CNMR spectrum of compound 9q.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hashemi, A., Noori, M., Dastyafteh, N. et al. Synthesis and tyrosinase inhibitory activities of novel isopropylquinazolinones. BMC Chemistry 17, 65 (2023). https://doi.org/10.1186/s13065-023-00978-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13065-023-00978-3

Keywords

BMC Chemistry

ISSN: 2661-801X

Contact us